In this article (Clin Cancer Res 2015;21:5499–510), which was published in the December 15, 2015, issue of Clinical Cancer Research (1), the grant support is listed incorrectly. It should read as follows: “J. Baselga was recipient of a FIS Grant Award (PI09/00623 and RD06/0020/0075), a ‘Tumor Biomarkers Collaboration’ supported by the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation and a private donation from the Orozco family through the Oncology Research Foundation (FERO). In addition, this study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748. V. Serra is recipient of an Instituto de Salud Carlos III (ISCIII) grant FIS PI13/01714 and a GHD/FERO grant. This work was also supported by the FP7-HEALTH-2010 COLTHERES grant (to J. Tabernero); the PI11/00917 Instituto de Salud Carlos III grant (to J. Tabernero); the AIRC (Associazione Italiana per la Ricerca sul Cancro) Investigator Grant 14205 and AIRC 2010 Special Program Molecular Clinical Oncology 5×1000, project 9970 (to L. Trusolino); the AACR, American Association for Cancer Research—Fight Colorectal Cancer Career Development Award (to A. Bertotti); the AIRC Investigator Grant 15571 (to A. Bertotti); and the unrestricted help of the Cellex Foundation. R. Dienstmann is a recipient of ‘La Caixa International Program for Cancer Research & Education.’” The authors regret this error.
Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res 1 August 2016; 22 (15): 3982. https://doi.org/10.1158/1078-0432.CCR-16-1206
Download citation file:
Citing articles via